Browsing by Author "Freire, P"
Now showing 1 - 10 of 18
Results Per Page
Sort Options
- Adenocarcinoma do pâncreas localmente avançado e metastizado com resposta completa a quimioterapiaPublication . Freire, P; Coelho, AJ; Rodrigues, A; Silva, MR; Lapa, P; Graça, B; Porto, AOs autores apresentam o caso clínico de doente do sexo feminino, 54 anos, raça branca, que recorreu ao médico assistente por dor abdominal associada a manifestações constitucionais. A ecografia revelou massa pancreática e formações nodulares hepáticas compatíveis com lesões secundárias, resultado posteriormente corroborado por tomografia computorizada, que acrescentou critérios de irressecabilidade, nomeadamente invasão dos vasos mesen- téricos e do duodeno. A biopsia ecoguiada obteve material cujo estudo anatomopatológico revelou tratar-se de adeno- carcinoma do pâncreas. Iniciou quimioterapia, verifican- do-se melhoria clínica progressiva. A reavaliação imagio- lógica, após 7 ciclos de tratamento, não detectou a lesão primitiva nem as lesões secundárias, sugerindo resposta completa. Foi mantido esquema regular de quimioterapia, persistindo a remissão 8 meses após a documentação da resposta completa.
- Capsule endoscopy assisted by traditional upper endoscopyPublication . Almeida, N; Figueiredo, P; Lopes, S; Freire, P; Lérias, C; Gouveia, H; Leitão, MBACKGROUND AND AIMS: Capsule endoscopy (CE) can be prevented by difficulties in swallowing the device and/or its gastric retention. In such cases, endoscopic delivery of the capsule to duodenum is very useful. We describe the indications and outcomes of cases in which traditional endoscopic techniques allowed placement of the capsule in duodenum. PATIENTS AND METHODS: This is a retrospective, descriptive case series. All patients in the above conditions were identified and indications for CE, endoscopic-placement technique, complications and completeness of small bowel imaging were registered. RESULTS: Endoscopic-assisted delivery of the capsule was necessary in 13 patients (2.1% of all CE; 7 males; mean age--47.9 +/- 24.9 years, range 13 to 79 years). Indications for endoscopic delivery included: inability to swallow the capsule (7), gastric retention in previous exams (3), abnormal upper gastrointestinal anatomy (3). In eight patients, the capsule was introduced in GI tract with: foreign body retrieval net alone (3), retrieval net and a translucent cap (2), prototype delivery device (2) or a polypectomy snare (1). Five patients ingested the capsule that was then placed in duodenum with a polypectomy snare (3) or a retrieval net (2). No major complications occurred. Complete small bowel examination was possible in 10 patients (77%). CONCLUSIONS: Endoscopic placement of capsule endoscope in the duodenum is rarely needed. However it may be safely performed by different techniques avoiding some limitations of CE. The best methods for endoscopic delivery of the capsule in the duodenum seem to be retrieval net with a translucent cap when the patient is unable to swallow the device or a retrieval net only to capture the capsule in the stomach when the patients swallows it easily.
- Capsule endoscopy in inflammatory bowel disease type unclassified and indeterminate colitis serologically negativePublication . Lopes, S; Figueiredo, P; Portela, F; Freire, P; Almeida, N; Lérias, C; Gouveia, H; Leitão, MCBACKGROUND: The value of capsule endoscopy in the setting of inflammatory bowel disease type unclassified (IBDU) and indeterminate colitis (IC) remains obscure. The aim was to evaluate the clinical impact of capsule endoscopy on IBDU/IC patients with negative serology. METHODS: Eighteen patients with long-standing IBDU (n = 14) and IC (n = 4) were enrolled to undergo a capsule endoscopy and then followed prospectively. Lesions considered diagnostic of Crohn's disease (CD) were 4 or more erosions/ulcers and/or a stricture. The median follow-up time after capsule endoscopy was 32 ± 11 months (23-54 months). RESULTS: Total enteroscopy was possible in all patients. In 2 patients the examination was normal (Group 1). In 9 patients subtle findings were observed (Group 2): focal villi denudation (n = 1) and fewer than 4 erosions/ulcers (n = 8). In 7 patients, 4 or more erosions/ulcers were detected (Group 3), leading to a diagnosis of CD. However, their treatment was not reassessed on the basis of the capsule findings. Until now, a definitive diagnosis has been achieved in 2 additional patients: 1 from Group 1 (ulcerative colitis) and another patient from Group 2 (CD), who began infliximab infusions. Nine patients remained indeterminate at follow-up. CONCLUSIONS: Although capsule endoscopy enabled the diagnosis of CD in 7 patients, in none of them was the clinical management changed. Moreover, a change in therapy due to a diagnosis of CD was made for only 1 patient, who presented nonspecific findings. Our results suggest that capsule findings are not helpful in the work-up of these patients
- CARD15 mutations and colorectal cancer in a South European countryPublication . Freire, P; Portela, F; Donato, MM; Figueiredo, M; Amaro, P; Sá, A; Andrade, P; Gouveia, H; Sofia, CPURPOSE: CARD15 mutations are associated with higher susceptibility to Crohn's disease (CD) and longstanding colonic CD increases the risk of developing colorectal cancer (CRC). The relation between these mutations and sporadic CRC remains controversial. The aim of this study was to assess whether germline and/or somatic CARD15 mutations are risk factors for sporadic CRC in Portugal and whether there are genotype-phenotype correlations in these patients. METHODS: The three main CARD15 mutations (R702W, G908R and 3020insC) were researched in 112 sporadic CRC patients and 152 healthy subjects. RESULTS: Overall, CARD15 mutations were found in 18 patients (16.1%) and in 15 controls (9.9%; p = 0.132). Individually, the incidence of R702W was significantly higher in patients than in controls (12.5% vs. 5.3%, p = 0.035), whereas the genotype frequencies for G908R (2.7% vs. 3.3%) and 3020insC (0.9% vs. 1.3%) were not statistically different between the two groups. Entire genotypic agreement was found in patients genotyped for blood and neoplastic DNA. A significantly higher incidence of CARD15 mutations was detected in patients with CRC diagnosed under 60 years old (28.6% vs. 10.4%, p = 0.015) and in female patients (24.4% vs. 10.4%, p = 0.048). No associations were found between CARD15 mutations and family history, symptoms or CRC pathologic characteristics. CONCLUSIONS: The CARD15 R702W variant might be a predisposing factor to sporadic CRC in Portugal, particularly in patients under 60-years old and in female patients. This susceptibility appears to be linked with germline CARD15 mutations. Nevertheless, we have found no evidence that CARD15 mutations predict the pathologic characteristics of CRC.
- CARD15 Mutations and Colorectal Cancer in a South European CountryPublication . Freire, P; Portela, F; Donato, MM; Figueiredo, P; Duque, G; Ferreira, M; Amaro, P; Sá, A; Andrade, P; Gouveia, H; Sofia, C
- CARD15 Mutations and Perianal Fistulating Crohn’s Disease: Correlation and Predictive Value of Antibiotic ResponsePublication . Freire, P; Portela, F; Donato, MM; Ferreira, M; Andrade, P; Sofia, CBACKGROUND: CARD15 mutations alter bowel immunity and increase susceptibility to Crohn's disease (CD). However, the relation between these mutations and Crohn's perianal fistulas has not been fully clarified. AIMS: To assess whether CARD15 mutations are associated with risk of developing Crohn's perianal fistulas and whether these mutations are predictors of the response of perianal fistulas to antibiotics. METHODS: CARD15 mutations were investigated in 203 consecutive CD patients. Presence/absence of history of perianal fistula was recorded. Patients with history of perianal fistula were divided into two groups (with/without CARD15 mutations), and response to antibiotics was evaluated in both groups. RESULTS: Of the 203 patients, 60 (29.6%) showed at least one CARD15 mutation and 55 (27.1%) had history of perianal fistula. History of perianal fistula was identified in 13 (21.7%) patients with mutations and in 42 (29.4%) patients without mutations (P = 0.260). Mean age at diagnosis of first perianal fistula was similar in patients with/without CARD15 mutations (28.7 +/- 9.8 versus 29.7 +/- 10.1 years, P = 0.758). Average time between disease onset and diagnosis of first perianal fistula was also similar in the two groups (4.6 +/- 5.1 versus 5.0 +/- 5.9 years, P = 0.816). Response of perianal fistulas to antibiotics (metronidazole alone or combined with ciprofloxacin) was significantly higher in patients without CARD15 mutations (7.7% versus 40.5%, P = 0.041). CONCLUSIONS: In CD, CARD15 mutations are not associated with risk of developing perianal fistulas or with time of their outbreak. Nevertheless, patients with perianal fistulas and CARD15 mutations showed worse response to antibiotics.
- O Doente Cirrótico na Unidade de Cuidados Intensivos: Avaliação do PrognósticoPublication . Freire, P; Romãozinho, JM; Ferreira, M; Amaro, P; Leitão, MINTRODUÇÃO: Os doentes com cirrose hepática admitidos em Unidades de Cuidados Intensivos (UCI) têm um prognóstico particularmente reservado. O prognóstico destes doentes pode ser avaliado com scores gerais (SOFA, APACHE, SAPS) ou com scores específicos de cirrose hepática (MELD, Child-Pugh). OBJECTIVOS: Avaliar o valor prognóstico dos scores gerais (SOFA, APACHE e SAPS) e dos scores específicos de cirrose hepática (MELD e Child-Pugh) em doentes com cirrose hepática admitidos em UCI polivalentes ou em Unidades de Cuidados Intensivos de Gastrenterologia (UCIGE). MATERIAL E MÉTODOS: Os autores fazem uma revisão da literatura sobre a avaliação do prognóstico de doentes com cirrose hepática admitidos em ICUs e relatam também a sua experiência sobre esta temática no contexto duma UCIGE incluindo a análise de 124 internamentos. RESULTADOS: Nos diversos estudos efectuados em doentes com cirrose hepática admitidos em UCI polivalentes, os diferentes scores gerais e específicos revelaram um bom poder discriminativo, ou seja, com uma área sob a curva ROC (AUC) > 0,7. Considerando os seis estudos mais representativos, o valor médio da AUC dos scores SOFA, APACHE II, APACHE III, MELD e Child-Pugh foi 0,86, 0,74, 0,81, 0,79 e 0,77, respectivamente. O estudo de 124 internamentos consecutivos na UCIGE de doentes com cirrose hepática revelou que os doentes que faleceram pertenciam todos à classe C de Child-Pugh e tinham valores médios dos scores SOFA, APACHE II, SAPS II e MELD significativamente superiores aos dos doentes que não faleceram (10,1, 22,0, 47,5 e 30,7 nos que faleceram e 3,5, 13,6, 25,4 e 18,0 nos que não faleceram, respectivamente; p >< 0,05). Conclusões: Tanto os scores gerais como os específicos de cirrose hepática têm valor prognóstico na avaliação do risco de doentes com cirrose hepática internados em UCI polivalentes ou em UCIGE. Nas UCI polivalentes os scores gerais, e em particular o SOFA, apresentam melhor capacidade prognóstica do que os scores específicos de cirrose hepática
- Epigastralgias por osso espetado na parede gástricaPublication . Freire, P; Gomes, D; Sousa, H; Portela, F; Andrade, P; Lopes, S; Alves, S; Gouveia, H; Leitão, M
- Esofagite eosinofílica com aspecto endoscópico peculiarPublication . Freire, P; Portela, F; Rodrigues, A; Silva, MR; Andrade, P; Gouveia, H; Leitão, M
- Glycogenic acanthosis of the esophagus: an unusually endoscopic appearancePublication . Lopes, S; Figueiredo, P; Amaro, P; Freire, P; Alves, S; Cipriano, MA; Gouveia, H; Sofia, C; Leitão, M